Scientists have shown that culturing cells with a modified serum could allow drugs to be screened for toxicity earlier during research.
List view / Grid view
Filter the results
Researchers have shown that an mRNA delivery system can be used to produce the BDNF protein in rats to protect neurons from ischemia.
Using cryo-electron microscopy, researchers have shown that the Spike (S) protein on cells exposed to the AstraZeneca vaccine is highly similar to the SARS-CoV-2 S protein.
Researchers have created a new single-cell transcriptomics approach that cryopreserves cells, limiting the stress they are put under.
A model of the SARS-CoV-2 Spike protein surface has uncovered vulnerabilities that researchers say could inform the development of COVID-19 vaccines.
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
The Atlas of Variant Effects Alliance will develop a map of human genetic variants to advance the understanding and treatment of disease.
A new VLP-based Zika virus vaccine is able to protect mice completely from infection, researchers have found.
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
A team has designed gold nanoparticles to reveal specific bone stem cells, which could lead to treatments for major bone fractures.
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
A combination of checkpoint and small molecule inhibitors showed success at targeting Myc oncogenes in mouse neuroblastoma and melanoma models.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.